HCA operates 186 hospitals and roughly 2,400 outpatient facilities across the US, generating revenue from inpatient admissions, emergency care, and surgical procedures. The company benefits from structural tailwinds: an aging population driving higher admission volumes, limited supply of hospital beds in many markets, and pricing power that outpaces medical cost inflation. Near-term growth hinges on elective procedure recovery and margin expansion as labor costs stabilize after pandemic-driven wage inflation. Trading at 14.1x forward earnings with an operating margin of 15.2%, HCA offers valuation that does not yet reflect normalized procedure volumes or the full benefit of operational leverage as staffing costs moderate. The 136% ROE reflects substantial financial leverage, which amplifies returns in a business with predictable cash flows but also warrants scrutiny on debt levels and refinancing risk in a higher-rate environment.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 18 Oct 2026, 17:04 CEST | Rating | Undervalued | first publication | $459 |
| 14 Oct 2026, 00:00 CEST | Fair value | $537 | $530 | $459 |
| 10 Oct 2026, 00:00 CEST | Fair value | $530 | $564 | $445 |
| 4 Oct 2026, 00:00 CEST | Fair value | $564 | $571 | $427 |
| 23 Sept 2026, 00:00 CEST | Fair value | $571 | $579 | $426 |
| 18 Sept 2026, 00:00 CEST | ACCE price target | $480 | first publication | $429 |
| 14 Sept 2026, 00:00 CEST | Fair value | $579 | $594 | $427 |
| 11 Sept 2026, 00:00 CEST | Fair value | $594 | $581 | $422 |
| 4 Sept 2026, 00:00 CEST | Fair value | $581 | $588 | $402 |
| 31 Aug 2026, 00:00 CEST | Fair value | $588 | $958 | $418 |
Answered from HCA Healthcare Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| HCA HCA Healthcare Inc. Common Stock | $469.03 | $532 | 12% below | 15.7x | 136.3% | 68 | 66 |
| FRE.DE Fresenius | €45.31 | €50 | 10% below | 16.6x | 8.3% | 59 | 63 |
| THC Tenet Healthcare Corporation Common Stock | $270.63 | $329 | 18% below | 10.3x | 37.3% | 68 | 81 |
| EHC Encompass Health Corporation Common Stock | $126.01 | $96 | 31% above | 20.8x | 25.0% | 72 | 69 |
| FME.DE Fresenius Medical Care | €39.18 | €58 | 32% below | 12.2x | 8.5% | 51 | 55 |
| FMS Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) | $22.23 | $33 | 33% below | 11.7x | 8.5% | 56 | 55 |
| DVA DaVita Inc. Common Stock | $186.10 | $263 | 29% below | 15.7x | 88.5% | 64 | 76 |
Where HCA ranks against its sector peers on each metric.